What Is Lifting OraSure's (NASDAQ:OSUR) Revenue 14% Year Over Year?

Sonal Goyal

10 November 2026 06:56 PM AEDT

What Is Lifting OraSure's (NASDAQ:OSUR) Revenue 14% Year Over Year?

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Key Highlights

Total net revenues were $30.9 million in the third quarter of 2026, up 14% year over year.
Sample Management Solutions Revenue rose 21% to $12.5 million.
Revenue excluding COVID-19 and Risk Assessment Testing was also $30.9 million, up 14%.
Revenue in one diagnostics line increased 16% to $16.8 million on higher HIV and HCV revenue.

OraSure Technologies, Inc. (NASDAQ:OSUR) reported third-quarter 2026 total net revenues of $30.9 million, up 1% from the second quarter and 14% from a year earlier. The company's chief executive described the result as double-digit growth delivered alongside progress in its strategy.

Segment Growth

Sample Management Solutions revenue was $12.5 million in the third quarter, an increase of 21% from the prior-year period.

A second diagnostics line recorded revenue of $16.8 million, up 16% year over year. The company attributed that increase to higher HIV and HCV revenue and to additional Business in the period.

Outlook and Considerations

Diagnostics companies face competitive pricing, reimbursement pressure and changes in testing guidelines, all of which can affect revenue.

Final Word

OraSure's third quarter shows total revenue of $30.9 million, up 14%, with sample management solutions up 21% and the core infectious disease line up 16%. Revenue excluding pandemic-related testing grew at the same pace.

FAQs

Q: What were OraSure's third-quarter 2026 revenues?

A: Total net revenues were $30.9 million, up 14% from the prior-year period.

Q: How did Sample Management Solutions perform?

A: Sample Management Solutions revenue rose 21% to $12.5 million.

Q: Did pandemic-related testing drive the growth?

A: Revenue excluding COVID-19 and Risk Assessment Testing grew 14% to $30.9 million, the same rate as total revenue.

Q: What drove the second diagnostics line?

A: The company attributed a 16% increase to $16.8 million to higher HIV and HCV revenue and additional business in the period.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.